Harriet Noble - Nursing Science

Author Information

Harriet Noble is affiliated with the Critical Care department at King's College Hospital, Denmark Hill, London SE5 9RS, UK, and the Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care at King's College London, James Clerk Maxwell Building, 57 Waterloo Road, London SE1 8WA, UK. Her work primarily focuses on critical care and nursing, making significant contributions to the field of healthcare.

Research Contributions

Harriet Noble has a distinguished record of research contributions, particularly in the area of critical care and nursing. She has been involved in numerous high-impact studies, including randomised controlled trials related to COVID-19 treatments such as casirivimab, imdevimab, convalescent plasma, and tocilizumab. Her work also extends to the impact of ICU design on patients, families, and medical teams, as well as the use of neurally adjusted ventilatory assist in critical care settings. Harriet's research is published in prestigious journals, indicating the high relevance and impact of her studies on the medical community.

Aliases

H Noble, H. Noble, Harriet Noble, Harriet Noble

Publication and Citation Metrics

Publication Year	Title	DOI
2022	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	10.1016/S0140-6736(22)00163-5
2021	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial	10.1016/S0140-6736(21)00897-7
2021	Early sedation with dexmedetomidine in ventilated critically ill patients and heterogeneity of treatment effect in the SPICE III randomised controlled trial	10.1007/s00134-021-06356-8
2021	Mapping the impact of ICU design on patients, families and the ICU team: A scoping review.	10.1016/j.jcrc.2021.07.002
2021	Postoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial.	10.1016/S2213-2600(21)00089-8
2021	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	10.1016/S0140-6736(21)00676-0
2021	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial	10.1007/s00134-021-06448-5
2020	Factors affecting the use of neurally adjusted ventilatory assist in the adult critical care unit: a clinician survey	10.1136/bmjresp-2020-000783
2020	Neurally adjusted ventilatory assist versus pressure support ventilation: a randomized controlled feasibility trial performed in patients at risk of prolonged mechanical ventilation	10.1186/s13054-020-02923-5
2018	Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data	10.1136/rmdopen-2018-000721